Claims for Patent: 10,280,468

Summary for Patent: 10,280,468

Title:	Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
Abstract:	Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
Inventor(s):	Harkin; Denis Paul (Dromore, GB), Kennedy; Richard (Belfast, GB), Keating; Katherine E. (Magherafelt, GB), McCavigan; Andrena (Derryadd Lurgan, GB), Hill; Laura A. (Lisburn, GB), Deharo; Steve (Belfast, GB), Davison; Timothy (Hillsborough, GB), Patterson; Fionnuala (Hauxton, GB), Donegan; Sinead (Belfast, GB), Jellema; Gera (Portadown, GB), Gourley; Charlie (Dumfermline, GB)
Assignee:	Almac Diagnostics Limited (Craigavon, GB)
Application Number:	15/116,641
Patent Claims:	1. A method for diagnosing and treating a patient suffering from a subtype of cancer which is resistant to anti-angiogenic therapy, comprising: obtaining a cancer sample from the patient; measuring expression levels of a biomarker panel in the cancer sample, wherein the biomarker panel is a ten-biomarker panel comprising at least IGF2, TAP1, SHISA4, ENTPD7, CDR1, SPARC, INS, NUAK1, and MATN3; determining a cancer sample expression score for the biomarker panel based on the measured expression levels; comparing the cancer sample expression score to a threshold expression score, derived from a cohort of patients with a known status of responsiveness to an anti-angiogenic agent; and treating the patient with at least one of a platinum-based chemotherapeutic agent and a mitotic inhibitor, but not an anti-angiogenic agent if the cancer sample expression score is above or equal to the threshold expression score. 2. The method of claim 1, wherein the cancer is ovarian cancer or colorectal cancer. 3. A method for diagnosing and treating a patient suffering from a subtype of cancer which is resistant to bevacizumab, comprising: obtaining a cancer sample from the patient; measuring expression levels of a biomarker panel in the cancer sample, wherein the biomarker panel is a ten-biomarker panel comprising at least IGF2, TAP1, SHISA4, ENTPD7, CDR1, SPARC, INS, NUAK1, and MATN3; determining a cancer sample expression score for the biomarker panel based on the measured expression levels; comparing the cancer sample expression score to a threshold expression score, derived from a cohort of patients with a known status of responsiveness to an anti-angiogenic agent; and treating the patient with at least one of a platinum-based chemotherapeutic agent and a mitotic inhibitor, but not bevacizumab if the cancer sample expression score is above or equal to the threshold expression score. 4. The method of claim 3, wherein the cancer is ovarian cancer or colorectal cancer.

Details for Patent 10,280,468

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2034-05-28